Ranolazine in patients with chronic coronarysyndromes: real-world data provide newevidence on the antiarrhythmic properties of the drug
Aims: Ranolazine (Ran) is an anti-anginal drug inhibiting late sodium current, an action possibly hindering arrhythmias onset. Indeed, some evidence supports the anti-arrhythmic effects of Ran. The aim of this study, which evaluated Italian patients withchronic coronary syndrome (CCS), was to investigate whether Ran, as an add-on therapy, was associated with a lower incidenceof atrial… Read More »Ranolazine in patients with chronic coronarysyndromes: real-world data provide newevidence on the antiarrhythmic properties of the drug
Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting
BACKGRO UND : PCSK9 inhibitors (PCSK9i) in combination with high-dose statins can reduce LDL -cholesterol (LDL-C) levels by 50-60% over statin monotherapy. This analysis investigated biochemical (LDL-C reduction) and economic outcomes in Italian patients treated with PCSK9i or potentially eligible but untreated.METHOD S: Administrative databases of healthcare institutions covering around 5 million residents were used… Read More »Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting
Evoluzione dei trattamenti per l’angioedema ereditarioin Italia: utilizzo del lanadelumab nella pratica clinica
Introduction: Hereditary angioedema (HEA) is a rare genetic disorder characterised by recurrent episodes ofedema affecting various body districts. HEA therapy includes treatment of acute attacks and short- or long-termprophylaxis.Objective: To describe the main demographic and clinical characteristics of patients with HEA in real Italian clinicalpractice, as well as the use of pharmacological treatments, the use… Read More »Evoluzione dei trattamenti per l’angioedema ereditarioin Italia: utilizzo del lanadelumab nella pratica clinica
Demographics and Clinical Burden of Disease Among RSV-Hospitalized Older Adults in Italy: A Retrospective Cohort Study
Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection and can lead to severe disease in older adults or those with comorbidities. This analysis aims to evaluate the demographic and clinical burden of RSV hospitalizations among older adults in Italy and inform potential preventative strategies. Adults aged ≥50 years with ≥1 hospitalization discharge diagnosis for RSV from 2010 to 2021 were included. Demographic characteristics before the first RSV hospitalization and clinical outcomes during this hospitalization and the 12 months following are described. Of the 243 patients, mean (SD) age was 73.7 (13.1) years, 40.7% were male, and the most common comorbidities were chronic obstructive pulmonary disease (37.9%), diabetes (21.8%), and heart failure (15.2%). Mean length of index hospitalization was 17.0 days, during which 9.1% of patients died. At index or during the 12-month follow-up, 5.8% had an intensive care unit admission, 61.3% were prescribed antibiotics, 8.2% had a stroke, and 3.3% had an acute myocardial infarction. During the 12-month follow-up, approximately, half of patients experienced worsening of preexisting comorbidities, with notable rates of re-hospitalization and mortality (44.4% and 29.6%). This study shows a high clinical burden of RSV among older adults in Italy, emphasizing a need for improved RSV surveillance, and may guide policymakers and healthcare providers in making informed recommendations for, and implementation of, RSV vaccination in Italy.
The Economic Burden of Herpes Zoster in Individuals Aged 50 Years or Older and Those With Underlying Conditions in Italy
Background: Risk of herpes zoster (HZ) infection increases with age and immunosuppression. We estimated the impact of HZ and post-herpetic neuralgia (PHN) on direct costs and health care resource utilization (HCRU) in patients ≥50 years, including those with comorbidities, as limited information exists in Italy.
Methods: This retrospective analysis used reimbursement data from local health authorities in Italy (January 2009-June 2022). Cases of HZ and PHN identified by International Classification of Diseases, Ninth Revision, Clinical Modification codes and drug prescriptions were characterized and followed up for 1 year before and after the index date. The direct HCRU costs for patients with HZ/PHN were compared with those for patients without HZ/PHN.
Results: Of the total 193 259 patients with HZ/PHN identified (mean age, 61.6 years), 145 923 were ≥50 years old (immunocompromised: 29.9%; ≥1 chronic condition: 76.1%). During follow-up, 18.8% of patients ≥50 years of age with HZ progressed to PHN complications, and 3618 hospital admissions were reported (median length of stay, 9 days). Drug prescriptions and all-cause hospitalizations were the main contributors to total annual direct health care costs, estimated at M€272 for patients with HZ/PHN, whose burden increased with age. Higher health care costs were observed in patients with HZ/PHN vs patients without HZ/PHN. Moreover, average health care costs were up to 4× higher for patients with HZ and PHN compared with those without PHN.
Conclusions: HZ causes a significant economic impact on the health care system, driven mainly by high costs of medications and hospitalizations among older adults and those with comorbidities, particularly when complicated by PHN.
Differential Adherence to Free and Single‑Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real‑World Analysis in Italy
Abstract Introduction Adherence to cardiovascular drug treatment can significantly benefit from a reduced pill burden, but data on this matter derived from real-life settings are currently scanty. This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/EZE as single-pill combination in… Read More »Differential Adherence to Free and Single‑Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real‑World Analysis in Italy
Real world evidence: patients with alopecia areata in Italy
BACKGROUN D: This real-world analysis aimed at characterizing patients hospitalized for alopecia areata (AA ) in Italy, focusing on comorbidities, treatment patterns and the economic burden for disease management.METHODS: Administrative databases of healthcare entities covering 8.9 million residents were retrospectively browsed to include patients of all ages with hospitalization discharge diagnosis for AA from 2010… Read More »Real world evidence: patients with alopecia areata in Italy
Analisi del percorso terapeutico e del consumo di risorse sanitarie in pazienti diabetici in trattamento insulinico: uno studio di real-world evidence su un campione di ASL della regione Sicilia
Italian reports indicate that more than one-third of patients with type 2 diabetes (T2D) require insulin therapy within 8 years of diagnosis, and commonly basal insulin represents the frontline option. An observational analysis was conducted with the aim of investigating patients treated with basal insulin alone in a sample of Local health Units of Sicily… Read More »Analisi del percorso terapeutico e del consumo di risorse sanitarie in pazienti diabetici in trattamento insulinico: uno studio di real-world evidence su un campione di ASL della regione Sicilia
Profile, Healthcare Resource Consumption and Related Costs in ANCA-Associated Vasculitis Patients: a Real-World Analysis in Italy
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare autoimmune diseases triggeringinflammation of small vessels. This real-world analysis was focused on the most common AAV forms, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), to describe patients’ demographic and clinical characteristics,therapeutic management, disease progression, and the related economic burden. A retrospective analysis was conducted on administrative… Read More »Profile, Healthcare Resource Consumption and Related Costs in ANCA-Associated Vasculitis Patients: a Real-World Analysis in Italy
A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn’s disease patients treated with biologics
Background/aims: This real-world analysis evaluated the persistence and direct healthcare costs of Crohn’s Disease (CD) patients treated with biologics in Italy. Methods: A retrospective analysis on administrative databases of Italian healthcare entities, covering 10.4 million residents, was performed. Adult CD patients under biologics between 2015 and 2020 were in- cluded and attributed to first/second treatment… Read More »A retrospective analysis of treatment patterns, drug discontinuation and healthcare costs in Crohn’s disease patients treated with biologics